Track the Rekvina Laboratories stock price and the full insider trade history of the company, a listed issuer based in India. Shares are quoted on the IN market, under the supervision of SEBI (PIT + SAST). Market capitalisation: €542.2m. The latest transaction was filed on 19 August 2026 (Acquisition). Among the most active insiders: Amit Mukesh Shah. The full history is free.
4
Insider Decl.
n/a
Thresholds
€276,111
4 ops.
Buy Volume
n/a
n/a
Sell Volume
41Σ signal
Buys €276,111n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,723 of 29,064 companies
19.7
score / 100
Value
32
Quality
7
FCF yld-1.1%
Earn yld-0.5%
EV/EBITDA·
ROE·
Gross mgn6.6%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,099,820 shares@ ₹1.00100.0% of flowEquityAllotmentSEBI:a3581af5075567329b33eb3287c478adc61d0d6d
Canonical exit: 17 Nov 2026 (T+90)
4 of 4 declarations
About Rekvina Laboratories
Rekvina Laboratories is a company operating in the XBOM market. It specializes in the development and production of innovative pharmaceutical solutions.